



MARKET DATA

Symbol	ANX
Exchange	AMEX
Share Price	\$0.49
Shares Outstanding	90.3M
Market Cap:	\$44.18M

CONFERENCE OBJECTIVES

Partnering and licensing deals in European market, with Larger Pharmaceutical Distributors.

RECENT DEVELOPMENTS

Submission of a New Drug Application (NDA) for ANX-530 (vinorelbine emulsion) pursuant to Section 505(b)(2) anticipated in the fourth quarter of 2008.

Patient enrollment in registrational bioequivalence study of ANX-514 (docetaxel emulsion) anticipated to begin in April 2008, pending appropriate clearances.

Eric K. Rowinsky, M.D., Chief Medical Officer & Executive Vice President of ImClone Systems Inc. recently joined ADVENTRX's Board of Directors.

ADVENTRX presents ANX-530 (vinorelbine emulsion) pharmacokinetic data at the 2008 American Association for Cancer Research Annual Meeting (AACR).

ADVENTRX will present CoFactor Phase 2 breast cancer data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO).

Positive results from a registrational bioequivalence clinical study of ANX-530 (vinorelbine emulsion) recently announced. Pharmacokinetic equivalence, the primary endpoint of the study, was observed between ANX-530 and Navelbine. Furthermore, in post hoc analyses, relative to Navelbine, ANX-530 demonstrated a statistically significant reduction in injection site reactions.

PRODUCT AND PRODUCT CANDIDATE PIPELINE

LEAD PRODUCT CANDIDATES

ANX-530 (vinorelbine emulsion) is a novel emulsion formulation of vinorelbine (Navelbine®) that is designed to reduce the incidence and severity of vein irritation associated with IV-delivery of vinorelbine. Vinorelbine is indicated as a single agent or in combination with cisplatin for the treatment of advanced non-small cell lung cancer and has also shown activity in breast, ovarian and other cancers. A single registrational bioequivalence clinical study of ANX-530 is complete. Primary endpoint of pharmacokinetic equivalence between ANX-530 and Navelbine met. Furthermore, ANX-530 demonstrated a statistically significant reduction in injection site reactions when compared to Navelbine. ADVENTRX intends to submit a New Drug Application (NDA) for ANX-530 to the FDA in Q4 2008.

ANX-514 (docetaxel emulsion) is a novel emulsion formulation of the anticancer drug docetaxel (Taxotere®), and is formulated without polysorbate 80 or other detergents. ANX-514 is designed to reduce the incidence and severity of hypersensitivity reactions. The FDA has affirmed a Section 505(b)(2) NDA regulatory path for ANX-514 in the U.S. Patient enrollment in registrational bioequivalence clinical study of ANX-514 anticipated to begin in April 2008.

ANX-510, or CoFactor®, is a folate-based biomodulator designed to replace leucovorin as the preferred method to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapeutic agent 5-FU. Phase 2b clinical trial results in mCRC indicated clinical equivalence of CoFactor/5-FU to leucovorin/5-FU when 5-FU was administered via infusion. Results from three CoFactor clinical studies anticipated in mid 2008.



ADVENTRX Pharmaceuticals

6725 Mesa Ridge Rd, Suite 100
San Diego, CA 92121
(858) 552-0866
www.adventrx.com



Evan Levine
President, Director, & CEO

Company Description

ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates primarily for the treatment of cancer and infectious disease. The Company seeks to improve the performance and commercial potential of existing treatments by addressing limitations associated with these treatment regimens.